Aligos Therapeutics, Inc. announced that it has priced initial public offering of 10 million common shares at $15.00 per share, the midpoint of the range between $14.00 and $16.00 per share. The offering is expected to close on October 20, 2020.
In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock at the initial public offering price.
The company sees offering gross proceeds, before expenses, to be about $150.0 million, excluding any exercise of the underwriters' option to purchase additional shares.
Aligos' common stock began trading on the Nasdaq Global Select Market on October 16, 2020, under the ticker symbol "ALGS."
J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.
For comments and feedback contact: editorial@rttnews.com
